Managing Acquired Resistance to Third-Generation EGFR Tyrosine Kinase Inhibitors Through Co-Targeting MEK/ERK Signaling is a research paper published in Lung Cancer Targets and Therapy (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R01 CA223220
NCI NIH HHS
Grant: R01 CA245386
NCI NIH HHS
Grant: UG1 CA233259
NCI NIH HHS
Grant: P50 CA217691
National Institutes of Health
Grant: 1P50CA217691-01A1
Emory University Lung Cancer SPORE
National Institutes of Health
Grant: 3UG1CA233259-06S1
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
National Institutes of Health
Grant: 5R01CA245386-05
c-Myc modulation and its implications in EGFR-targeted cancer therapy
National Institutes of Health
Grant: 5R01CA223220-06
Modulation of death receptor 4 in EGFR-targeted cancer therapy
FWCI
2.22
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals